Based on the information you submitted
Patients with stage IB disease has T2a disease (i.e., Breslow thickness between 1.0-2.0 mm and with no ulceration).
According to the 2018 AJCC data, patients with stage IB have an excellent prognosis. Their5-year and 10-year melanoma-specific survival probabilities are 97% and 94%, respectively.
Adopted from NCCN Guideline 2022
The treatment consists of a standard excision of the tumor along with a standard surgical margin of 1 to 2 cm.
Sentinel lymph node biopsy (SLNB) is discussed and offered to the patient because the Breslow thickness of the primary melanoma is 1mm.
Routine imaging (e.g., X-ray or CT scan) or lab tests are not recommended. No other treatment modalities, such as immunotherapy or targeted therapy, are needed.
INTERVIEW WITH THE EXPERTS
Dr. Thomas Wang discusses the surgical management of stage IB disease
Dr. Thomas Wang explains the sentinel lymph node biopsy (SLNB) procedure
Dr. Thomas Wang describes explains the sentinel lymph node biopsy procedure
Dr. Thomas Wang discusses which patients need the sentinel lymph node biopsy (SLNB)
Dr. Dan Coit explains sentinel lymph node biopsy (SLNB), the consultation process for the sentinel lymph node biopsy (SLNB), and the day of the surgery
Dr. Dan Coit discusses the complications associated with the sentinel lymph node biopsy
Dr. Dan Coit discusses the controversy associated with the sentinel lymph node biopsy procedure